黄芪生脉饮防治柔红霉素急性心脏毒性的临床研究

Clinical study on Huangqi Shengmaiyin in preventing and treating acute cardiotoxicity caused by daunorubicin

目的探讨黄芪生脉饮对柔红霉素急性心脏毒性的保护作用。方法选择2018年7月至2020年7月在新昌县人民医院肿瘤内科住院化疗的恶性肿瘤患者59例,分成观察组和对照组,两组均采用柔红霉素注射液为主的化疗方案,观察组加黄芪生脉饮口服,观察两组患者化疗前后的心电图、超声心动图指标[左心室舒张末期内径(LVEDd)、左心室收缩末期内径(LVESd)、左心室射血分数(LVEF)],检测肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnI)水平。结果观察组患者心电图异常发生率低于对照组,差异有统计学意义(P<0.05)。观察组LVEDd、LVESd均小于对照组,差异均有统计学意义(均P<0.05)。观察组CK-MB及cTnI低于对照组,差异均有统计学意义(均P<0.05)。结论黄芪生脉饮可减轻柔红霉素对心肌细胞的损伤,减弱柔红霉素的心脏毒性,保护心脏功能。

Objective Observe the protective effect of Huangqi Shengmaiyin on acute cardiotoxicity caused by danuorubicin.Methods Fifty-nine patients with malignancy at the department of Oncology,the People's Hospital of Xinchang from July 2018 to July 2020 were recruited,and were randomly assigned to observation and control group.Both groups were given daunorubicin injection based chemotherapy,while the observation group had Huangqi Shengmaiyin added in the daunorubicin based regimen.The electrocardiogram(ECG),echocardiogram left ventricular end diastolic diameter(LVEDd),left ventricular end systolic diameter(LVESd),left ventricular ejection fraction(LVEF),creatine kinase-MB(CK-MB),troponin(cTnI)values of the two groups before and after treatment were recorded Results The incidence of abnormal ECG in the observation group was significantly lower than that of the control group(P<0.05).In addition to left ventricular ejection fraction(LVEF),left ventricular internal dimension diastole(LVEDd),left ventricular internal dimension systole(LVESd)values were significantly lower than those of the control group(all P<0.05).CK-MB and cTnI in the observation group was significantly lower than those in the control group(all P<0.05).Conclusion Huangqi Shengmaiyin can reduce the damage of daunorubicin to myocardial cells,allieviating the cardiotoxicity of daunorubicin,and protect cardiac function.